/ Application Note

CD3- CD56+ NK Cell Selection with MARS® Platform

NK cells are currently a major target of innovation in the field of cancer immunotherapy. Efforts aimed at developing and engineering NK cell-based cancer immunotherapy require clean and efficient methods of cell isolation at both small and large scales. The new MARS® Bar system enables a new generation of large scale, magnetic CD56+/CD3- cell isolation technology for the separation of Apheresis, Leukopaks, Whole Blood or Bone Marrow cell products.

Application note highlighting CD3- CD56+ NK Cell Selection with MARS Bar Platform